PTX is one step closer to finding a working cancer treatment
Prescient Therapeutics (ASX:PTX) has just released interim ‘durability data’ for its PTX-200 breast cancer trial. CEO Steven Yatomi-Clarke speaks with Jonathan Jackson about what this means and the way forward in its cancer trials.
PTX is bringing a new sense of hope to the field of cancer research and treatment with drug candidates that are intended not to directly remove or attack cancer cells, but instead provide selective support (or inhibition) of some of the body’s own cells in order to help a patient heal themselves.
S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.
Conflict of Interest Notice
S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.
The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.